SynCardia Systems has announced that more than 20 SynCardia certified centres representing four countries and more than 70 authors will present a record number of abstracts discussing the SynCardia temporary Total Artificial Heart at the annual meeting of the International Society for Heart & Lung Transplantation (ISHLT; Montreal, Canada, 24–27 April).
The SynCardia temporary Total Artificial Heart is the only FDA, Health Canada and CE-marked approved total artificial heart.
“Transplant programmes throughout the world are making the SynCardia Total Artificial Heart the new standard of care for end-stage biventricular heart failure,” said Michael Garippa, SynCardia chairman, CEO, president. “SynCardia Certified Centers have amassed a wealth of knowledge and experience in using the Total Artificial Heart, and sharing this information with the international transplant community is critical to creating and sustaining good patient outcomes worldwide.”
Key ISHLT presentations on the SynCardia Total Artificial Heart are:
Wednesday, 24 April 2013
- 15.25pm: Total Artificial Heart
Francisco A Arabia, Cedars-Sinai Heart Institute, Los Angeles, USA
SYMPOSIUM 13: Machines vs Medications for Biventricular Failure (2:15 PM-4:15 PM)
Room: 517CD
Thursday, 25 April 2013
- 17.30pm: Characteristics and survival of patients with the Total Artificial Heart implanted for indications other than biventricular failure
Poster Session 2: Mechanical Circulatory Support (10–18.30)
Room: 516
- 17.30pm: Clinical outcomes for INTERMACS profile 1 patient implanted with the Total Artificial Heart
Poster Session 2: Mechanical Circulatory Support (10–18.30)
Room: 516
Friday, 26 April 2013
- 17.15pm: Worldwide use of SynCardia Total Artificial Heart in adolescents: A 25-year experience
Concurrent Session 35: PEDS 2: Mechanical Circulatory Support in Children (16.00-17.30)Room: 513ABC
- 17.30pm: Home discharge and out-of-hospital follow-up of Total Artificial Heart patients supported by a portable driver
Poster Session 3: Mechanical Circulatory Support (9.00–18.30)
Room: 516 - 18.05pm: Long term results with Total Artificial Heart: Is it prime time for destination therapy? Mini Oral Session 7: Mechanical Circulatory Support II (17:30–18.30) Room: 513DEF
Saturday, 27 April 2013
- 13.03pm: The worldwide use of SynCardia Total Artificial Heart in patients with congenital heart disease
Concurrent Session 41: MCS 10: Outcomes Potpourri (12.15-13.30)
Room: 511
- 13.15pm: Artificial heart patients discharged home with a portable pneumatic driver – The pivotal US clinical trial experience
Concurrent Session 44: MCS 11: Translational Science and New Devices (12.15–13.30)Room: 513ABC
In addition, on Wednesday 24 April SynCardia will be hosting a panel discussion titled, “Moving Forward: the freedom experience, the bi-leaflet valve TAH, and end-organ recovery.”
Medical professionals interested in attending should contact Vivian Wessel at [email protected].
